scholarly journals Impact of immune thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction

2019 ◽  
Vol 43 (1) ◽  
pp. 50-59
Author(s):  
Omar Chehab ◽  
Nadine Abdallah ◽  
Amjad Kanj ◽  
Mohit Pahuja ◽  
Oluwole Adegbala ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Outcomes ◽  
Immune Thrombocytopenic Purpura ◽  
Thrombocytopenic Purpura

Invasive treatment performed for acute myocardial infarction in a patient with immune thrombocytopenic purpura

2008 ◽  
Vol 127 (3) ◽  
pp. e183-e185 ◽  
Author(s):  
Maria Cruz Ferrer Gracia ◽  
Isabel Calvo Cebollero ◽  
Juan Sánchez-Rubio Lezcano ◽  
Gabriel Galache Osuna ◽  
José Antonio Diarte Miguel ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Immune Thrombocytopenic Purpura ◽  
Invasive Treatment ◽  
Thrombocytopenic Purpura

scholarly journals Outcomes of Hospitalized Patients with Myocardial Infarction and Immune Thrombocytopenic Purpura: A Cross Sectional Study over 15 Years

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4977-4977
Author(s):  
Chisom Onuoha ◽  
Marcus Weldon ◽  
Vamsi Kota ◽  
Achuta Kumar Guddati
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Coronary Artery ◽  
Immune Thrombocytopenic Purpura ◽  
Hospitalized Patients ◽  
Blood Transfusions ◽  
Age Group ◽  
Thrombocytopenic Purpura ◽  
Acute Mi

Abstract Background: Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by low platelet counts and mucocutaneous bleeding. Antiplatelet agents are an essential component in the treatment of acute myocardial infarction (MI). Patients with ITP are not exempt from succumbing to acute myocardial infarction. Myocardial infraction in these patients is rare but poses a significant management challenge. The outcomes of hospitalized patients with ITP and acute MI have not been previously described and may help identify risk factors associated with adverse outcomes in this unique patient population. Methods: The International Classification of Diseases, 9th Edition, Clinical Modification codes were used to identify patients with ITP who were admitted with acute myocardial infarction. All data regarding such hospitalization was extracted from the National Inpatient Database for the years 2000 to 2014. Patient demographics of age, race and gender; hospital characteristics such as geographical location, teaching status, rural vs. urban location and bed size, medical comorbidities such as hypertension, hyperlipidemia, diabetes and coronary artery disease were studied. The Chi square test was used to determine associations with statistical significance and logistic regression was used to determine independent predictors of mortality. Results: A total of 753,732 hospitalized patients with ITP were identified over the time period of 2000 to 2014 of which 37695 patients had both ITP and acute MI. There were more females with ITP in general (60% females vs 40% males), but more males with ITP and acute MI (55.8% males vs 44.2% females; p =0.0000). Caucasians were affected the most (5.5%) amongst all races and the age group of 65-79 years had the highest percentage of patients with ITP and MI (7.3%). While hospitals located in the Northeast region of the country had the highest prevalence of MI in ITP, there was no statistical difference between prevalence in hospitals of different sizes (small vs. medium vs. large). A majority of patients with MI and ITP were covered by Medicare and were discharged home. 5572 patients received a stent and 3353 patients underwent coronary artery bypass grafting. The classical risk factors of hypertension, hyperlipidemia, and diabetes were also noted to be highly prevalent in patients with ITP and MI. 10.05% of patients with ITP and acute MI died during hospitalization, while 4% of all patients with ITP died during hospitalization (p<0.05). Multiple regression showed that stent placement, female gender, blood transfusions, platelet transfusion, 80+ age group and higher Charlson's score were independent predictors of mortality in patients with ITP who have MI (ORs: 0.3, 0.8, 1.9, 1.3, 5.9 and 5.5 respectively). Conclusions: ITP patients with MI have poor outcomes. Known risk factors for acute MI in the general population are also applicable to patients with ITP. Acute MI is associated with an increased rate of in-hospital death in patients with ITP. Both blood transfusions and platelet transfusions adversely affect outcomes and should be considered in the management of MI in ITP patients. Disclosures Kota: Novartis: Honoraria; Xcenda: Honoraria; Incyte: Honoraria; BMS: Honoraria; Pfizer: Honoraria.

P3603Impact of idiopathic thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
O Chehab ◽  
M Pahuja ◽  
O Adegbala ◽  
E Akintoye ◽  
P Ramia ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Hospital Mortality ◽  
Clinical Outcomes ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Coronary Revascularization ◽  
Bleeding Complications ◽  
Cardiac Complications ◽  
Thrombocytopenic Purpura ◽  
Secondary Outcomes

Abstract Background There is scarce evidence reflecting the clinical outcomes in patients with Idiopathic Thrombocytopenic Purpura (ITP) and Acute Myocardial Infarction (AMI). The ITP patient population is at higher risk of bleeding complications due to low platelet counts and difficulty in managing their antiplatelet and anticoagulation therapy. In our study, we sought to assess clinical outcomes of ITP patients admitted with AMI using the US national inpatient sample (NIS) database. Purpose To determine difference in in-hospital mortality, clinical complications, and length of stay (LOS) in AMI patients with and without ITP. Methods We identified adults aged ≥18 years hospitalized from 2005 to 2014 with AMI as their primary diagnosis utilizing ICD-9 codes 410.0 to 410.92. Patients with ITP were identified using ICD-9 code 287.31. The primary outcome was in-hospital mortality. Secondary outcomes included coronary revascularization procedures (PCI and CABG), and in-hospital complications including bleeding (intracranial, epistaxis, GI, and GU bleeding, hematoma, and bleeding requiring transfusion), cardiac complications, transfusions, acute ischemic stroke (AIS), and LOS. A propensity-matched cohort accounting for demographic characteristics, comorbidities, and cardiovascular risk factors, was created to compare these outcomes. Patients with secondary causes of ITP such as HIV, pregnancy, sepsis, SLE, malignancy were excluded. Results A total of 1108034 AMI admissions, of which 1002 with ITP, were identified. In the unmatched group, patients with ITP were older, and had more comorbidities (diabetes mellitus; hypothyroidism; atrial fibrillation; previous history of cardiovascular, peripheral, and end stage renal disease; all p<0.05). In the AMI population, 851 ITP and 851 non-ITP admissions were propensity-matched. Figure 1 illustrates the primary and secondary outcomes of the study among the propensity-matched study groups. Although there was no difference in short-term mortality between the ITP and non-ITP patients with AMI, patients with ITP were less likely to undergo coronary revascularization possibly because of thrombocytopenia. Patients with ITP had significantly more bleeding complications and transfusions. We observed in our study that patients with ITP had a significantly longer LOS compared to non-ITP patients (6.1 vs 5.4 days, with a mean ratio of 1.14 (95% CI: 1.05,1.23)). Conclusion In the large population of patients included in the NIS database, patients with ITP admitted with AMI, have a significantly higher rate of bleeding complications, undergo less PCI and have a longer LOS compared to AMI patients without ITP. There are no current guidelines by ACC/AHA/ESC regarding management of patients with AMI and thrombocytopenia. These results warrant further investigation through randomized controlled trials including patients with thrombocytopenia to assess long term outcomes and to define optimal management in this population.

scholarly journals Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yong Hoon Kim ◽  
Ae-Young Her ◽  
Myung Ho Jeong ◽  
Byeong-Keuk Kim ◽  
Sung-Jin Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Outcomes ◽  
Secondary Outcome ◽  
Drug Eluting Stent ◽  
Diabetes Group ◽  
Repeat Revascularization ◽  
Group A ◽  
Group B ◽  
Diabetes Patients

AbstractWe investigated the effects of stent generation on 2-year clinical outcomes between prediabetes and diabetes patients after acute myocardial infarction (AMI). A total of 13,895 AMI patients were classified into normoglycemia (group A: 3673), prediabetes (group B: 5205), and diabetes (group C: 5017). Thereafter, all three groups were further divided into first-generation (1G)-drug-eluting stent (DES) and second-generation (2G)-DES groups. Patient-oriented composite outcomes (POCOs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization were the primary outcome. Stent thrombosis (ST) was the secondary outcome. In both prediabetes and diabetes groups, the cumulative incidences of POCOs, any repeat revascularization, and ST were higher in the 1G-DES than that in the 2G-DES. In the diabetes group, all-cause death and cardiac death rates were higher in the 1G-DES than that in the 2G-DES. In both stent generations, the cumulative incidence of POCOs was similar between the prediabetes and diabetes groups. However, in the 2G-DES group, the cumulative incidences of Re-MI and all-cause death or MI were significantly higher in the diabetes group than that in the prediabetes group. To conclude, 2G-DES was more effective than 1G-DES in reducing the primary and secondary outcomes for both prediabetes and diabetes groups.

Sign in / Sign up

Export Citation Format

Share Document